Ignite Creation Date:
2025-12-25 @ 12:02 AM
Ignite Modification Date:
2026-04-17 @ 6:58 AM
Study NCT ID:
NCT05550558
Status:
NOT_YET_RECRUITING
Last Update Posted:
2022-09-28
First Post:
2022-09-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial Cancer
Sponsor:
Organization: